Immutep Advances LAG-3 Immunotherapy Trials

Immutep (IMMP) has released an update.

Immutep Limited, a biotechnology firm specializing in LAG-3 immunotherapies, has made significant strides in its clinical trials, including a pivotal Phase III trial for non-small cell lung cancer in collaboration with MSD. The company reported positive clinical data across several studies, including treatments for head and neck squamous cell carcinoma and metastatic breast cancer, while also solidifying its financial position with an extended cash runway until the end of 2026.

For further insights into IMMP stock, check out TipRanks’ Stock Analysis page.